Evidence map›Paper›PMID 31902266›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2020

Synthesis and biological evaluation of novel (

Jing-Wei Liang, Shi-Long Li, Shan Wang, Wan-Qiu Li, Fan-Hao Meng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Design and biological evaluation of 3-substituted quinazoline-2,4(1Journal of enzyme inhibition and medicinal chemistry · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jing-Wei LiangSchool of Pharmacy, China Medical University, Shen Yang, China.
Shi-Long LiSchool of Pharmacy, China Medical University, Shen Yang, China.
Shan WangSchool of Pharmacy, China Medical University, Shen Yang, China.
Wan-Qiu LiSchool of Pharmacy, China Medical University, Shen Yang, China.
Fan-Hao MengSchool of Pharmacy, China Medical University, Shen Yang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

C-Met plays a crucial role in the development and progression of neoplastic disease. Type II c-Met inhibitors recognise the inactive DFG-out conformation of the kinase, result in better anti-tumour effects due to synergistic effect against the other kinases. According to our previous works, an

Indexed as

Benzylidene CompoundsDrug DiscoveryHumansProtein Kinase InhibitorsProto-Oncogene Proteins c-metQuantitative Structure-Activity RelationshipVascular Endothelial Growth Factor Receptor-2Benzylidene CompoundsKDR protein, humanProtein Kinase InhibitorsProto-Oncogene Proteins c-metVascular Endothelial Growth Factor Receptor-2benzylidene hydrazidesc-Met inhibitorQSARVirtual screening

Identifiers

PMID31902266
PMCPMC6968643

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.